Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events

Diabetes, Obesity and Metabolism

Volumn 12, Issue 11, 2010, Pages 958-966

  Ahmed, M H ^a   Byrne, C D ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular disease; Ezetimibe; Gallstones; Insulin resistance; Non alcoholic fatty liver disease

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RAPAMYCIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG INHIBITION; DYSLIPIDEMIA; GALLSTONE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLEIOTROPY; REMISSION; REVIEW; TREATMENT OUTCOME;

EID: 77957267982     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01261.x     Document Type: Review

References (96)

1. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005, 44:467-494..
2. Davis HR. Altmann S.W. Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta 2009, 1791:679-683..
3. Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 2007, 12:740-747..
4. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of Hepatic Neiman-Pick C1-Like 1 Improves Hepatic Insulin Resistance. Am J Physiol Endocrinol Metab 2009, [Epub ahead of print].
5. Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 2007, 48:2725-2735..
6. Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006, 12:4369-4376..
7. Deushi M, Nomura M, Kawakami A. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007, 581:5664-5670..
8. Hughes EA, Tracey I, Singhal S, Patel J. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med Hypotheses 2006, 67:1463-1464..
9. Nozaki Y, Fujita K, Yoneda M. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009, 51:548-556..
10. Zheng S, Hoos L, Cook J. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008, 584:118-124..
11. Taylor AJ, Villines TC, Stanek EJ. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122..
12. Kastelein JJ, Akdim F, Stroes ES. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443..
13. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008, 358:1504-1507..
14. Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008, 54:940-942..
15. Karalis DG. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc 2009, 84:345-352..
16. Fleg JL, Mete M, Howard BV. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52:2198-2205..
17. Cannon CP, Giugliano RP, Blazing MA. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826-832..
18. Ara R, Tumur I, Pandor A. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess 2008, 12:xi-iii,212.. iii,
19. Sharma M, Ansari MT, Abou-Setta AM. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009, 151:622-630..
20. Rossebo AB, Pedersen TR, Boman K. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356..
21. Peto R, Emberson J, Landray M. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357-1366..
22. Pandor A, Ara RM, Tumur I. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009, 265:568-580..
23. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/ simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol 2009, 3(2):138-142..
24. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36..
25. Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernandez-Salazar E, Ramos-Zavala MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 2006, 20:143-146..
26. Enjoji M, Machida K, Kohjima M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 2010, 9:29..
27. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010, 33:1134-1139..
28. Abel T, Feher J, Dinya E, Eldin MG, Kovacs A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009, 15:MS6-11..
29. Abel T, Feher J, Dinya E, Gamal EM, Kovacs A. Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease. Orv Hetil 2009, 150:989-993..
30. Rudovich NN, Weickert MO, Machann J, Pfeiffer AF. Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance? J Hepatol 2010
31. Ahmed MH, Byrne CD. Metabolic syndrome, diabetes & CHD risk. CJ Packard. The Year in Lipid Disorders. 2007, 3-26.. Oxford, UK, Clinical publishing
32. Basciano H, Miller AE, Naples M. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab 2009, 297:E462-E473..
33. Matikainen N, Manttari S, Westerbacka J. Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007, 92:3052-3059..
34. Lin HJ, Lee BC, Ho YL. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diabetes Care 2009, 32:1721-1726..
35. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Prevalence of coronary heart disease among Tehran adults: Tehran Lipid and Glucose Study. East Mediterr Health J 2009, 15:157-166..
36. Bittner V, Johnson BD, Zineh I. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischaemia: a report from the Women's Ischaemia Syndrome Evaluation (WISE). Am Heart J 2009, 157:548-555..
37. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308..
38. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316..
39. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300:2142-2152..
40. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008, 118:993-1001..
41. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005, 7:132-140..
42. Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC. Strong association between gallstones and cardiovascular disease. Am J Gastroenterol 2005, 100:827-830..
43. Mendez-Sanchez N, Zamora-Valdes D, Flores-Rangel JA. Gallstones are associated with carotid atherosclerosis. Liver Int 2008, 28:402-406..
44. Loria P, Lonardo A, Lombardini S. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol 2005, 20:1176-1184..
45. Ramos-De la MA, Remes-Troche JM, Roesch-Dietlen FB, Perez-Morales AG, Martinez S, Cid-Juarez S. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg 2008, 12:2097-2102..
46. Mathur A, Walker JJ, Al-Azzawi HH. Ezetimibe ameliorates cholecystosteatosis. Surgery 2007, 142:228-233..
47. Zuniga S, Molina H, Azocar L. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008, 28:935-947..
48. Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008, 295:G813-G822..
49. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008, 134:2101-2110..
50. Ahmed MH, Byrne CD, Byrne C, Wild S. Non alcoholic steatatohepatitis and metabolic syndrome. Metabolic Syndrome. 2005, 279-305.. eds., Chichester, UK, John Wiley & Sons
51. Biddinger SB, Haas JT, Yu BB. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008, 14:778-782..
52. Chang Y, Sung E, Ryu S, Park YW, Jang YM, Park M. Insulin resistance is associated with gallstones even in non-obese, non-diabetic Korean men. J Korean Med Sci 2008, 23:644-650..
53. Nakeeb A, Comuzzie AG, Al-Azzawi H, Sonnenberg GE, Kissebah AH, Pitt HA. Insulin resistance causes human gallbladder dysmotility. J Gastrointest Surg 2006, 10:940-948..
54. Kasiske B, Cosio FG, Beto J. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004, 4((Suppl 7)):13-53..
55. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 2008, 17:450-456..
56. Chauveau P, Rigalleau V, Aparicio M. Insulin resistance and chronic kidney disease. Nephrol Ther 2008, 4:568-574..
57. Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. J Ren Nutr 2008, 18:70-75..
58. da Costa JA, Alp IT. Inflammation and insulin resistance as novel mechanisms of wasting in chronic dialysis patients. Semin Dial 2009, 22:652-657..
59. Nakamura T, Sato E, Fujiwara N. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010, 61:58-61..
60. Landray M, Baigent C, Leaper C. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006, 47:385-395..
61. Nakamura T, Sato E, Fujiwara N. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009, 60:525-528..
62. Kanbay M, Turgut F, Covic A, Goldsmith D. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 2009, 22:598-609..
63. Shehab-Eldin W, Shoeb S, Khamis S, Salah Y, Shoker A. Susceptibility to insulin resistance after kidney donation: a pilot observational study. Am J Nephrol 2009, 30:371-376..
64. Gnatta D, Keitel E, Heineck I. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. Transplant Proc 2010, 42:475-478..
65. Rodriguez-Ferrero ML, Anaya F. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients. Transplant Proc 2008, 40:3492-3495..
66. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006, 6:205-208..
67. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006, 6:770-774..
68. Chuang P, Langone AJ. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Am J Ther 2007, 14:438-441..
69. Turk TR, Voropaeva E, Kohnle M. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant 2008, 23:369-373..
70. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 2009, 15:504-508..
71. Koenig W, Sund M, Frohlich M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242..
72. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002, 89:145-149..
73. Sager PT, Melani L, Lipka L. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003, 92:1414-1418..
74. Ballantyne CM, Houri J, Notarbartolo A. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415..
75. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007, 99:1706-1713..
76. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008, 65:637-645..
77. Piorkowski M, Fischer S, Stellbaum C. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007, 49:1035-1042..
78. Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008, 29:1753-1760..
79. Fichtlscherer S, Schmidt-Lucke C, Bojunga S. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006, 27:1182-1190..
80. Landmesser U, Bahlmann F, Mueller M. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363..
81. Davis HR, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001, 21:2032-2038..
82. Dietrich T, Hucko T, Bourayou R. High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe. Int J Cardiovasc Imaging 2009, 25:827-836..
83. Graf K, Dietrich T, Tachezy M. Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis. Mol Imaging 2008, 7:68-76..
84. Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, Aragoncillo P, Granados R, Fernandez-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009, 156:1218-1227..
85. Rizzo M, Kotur-Stevuljevic J, Berneis K. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res 2009, 153:217-223..
86. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res 2006, 47:2575-2580..
87. Meaney A, Ceballos G, Asbun J. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009, 49:838-847..
88. van der GA, Cuffie-Jackson C, Vissers MN. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008, 52:1421-1429..
89. Ballantyne CM, Weiss R, Moccetti T. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007, 99:673-680..
90. Masuda D, Nakagawa-Toyama Y, Nakatani K. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698..
91. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475..
92. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007, 23:2009-2026..
93. Yoon HE, Song JC, Hyoung BJ. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med 2009, 24:233-237..
94. Lopez V, Gutierrez C, Gutierrez E. Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia. Transplant Proc 2008, 40:2925-2926..
95. Panichi V, Manca-Rizza G, Paoletti S. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Biomed Pharmacother 2006, 60:249-252..
96. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005, 37:1033-1035..